Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768935 | 0.88 | PARP1 (0.53) | PARP1ADORA2APTPRCTYMSALDH1A1 | |
| Formamide SCHEMBL6754148 | 0.81 | PARP1 (0.47) | PARP1ADORA2APTPRCTYMSHSD17B10 | |
| Urea SCHEMBL6754151 | 0.81 | BRD4 (0.48) | PARP1ADORA2APTPRCTYMSALDH1A1 | |
| SCHEMBL8502152 | 0.80 | PARP1 (0.48) | PARP1ADORA2APTPRCALDH1A1CASP1 | |
| SCHEMBL34471460 | 0.79 | ALDH1A1 (0.46) | PARP1TYMSALDH1A1GAACASP1 | |
| SCHEMBL5541367 | 0.76 | ALDH1A1 (0.41) | PARP1TYMSALDH1A1GAAKDM4E | |
| SCHEMBL4221971 | 0.75 | CES1 (0.59) | PARP1ADORA2APTPRCL3MBTL1MAOA | |
| SCHEMBL163925 | 0.74 | PARP10 (0.56) | TYMSALDH1A1GAAHSD17B10KDM4E | |
| SCHEMBL389461 | 0.74 | PARP1 (0.56) | PARP1ALDH1A1GAACASP1CASP7 | |
| SCHEMBL15386452 | 0.74 | ALDH1A1 (0.40) | PARP1PTPRCTYMSALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| CN-114369014-A | Synthetic method of aromatic substituted indanone compound | 山东京博生物科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| EP-0752991-B1 | IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONES ANTAGONISTS OF AMPA AND NMDA RECEPTORS | RHONE POULENC RORER SA (FR) | 1999-05-26 | — | — | EP | disclosed |
| US-5789406-A | Indeno 1,2-E!pyrazine-4-ones, their preparation and the medicaments containing them | RHONE-POULENC RORER S.A. (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0752991-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026349-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1995-10-05 | — | — | WO | disclosed |
| US-4234678-A | DEVELOPMENT INHIBITORS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1980-11-18 | — | — | US | disclosed |
| US-3988460-A | Cyclopentenoquinolone compounds for treating bacterial infections | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PARP1 999/4885ADORA2A 765/4885PTPRC 1620/4885 |
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | PARP1 828/4885ADORA2A 4781/4885PTPRC 1915/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | PARP1 828/4885ADORA2A 4781/4885PTPRC 1915/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | PARP1 483/4885ADORA2A 4617/4885PTPRC 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.